Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Top Cited Papers
- 1 February 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Gynecological Endocrinology
- Vol. 28 (7), 509-515
- https://doi.org/10.3109/09513590.2011.650660
Abstract
Polycystic ovary syndrome (PCOS) affects 5%–10% of women in reproductive age, and it is the most common cause of infertility due to ovarian dysfunction and menstrual irregularity. Several studies have reported that insulin resistance is common in PCOS women, regardless of the body mass index. The importance of insulin resistance in PCOS is also suggested by the fact that insulin-sensitizing compounds have been proposed as putative treatments to solve the hyperinsulinemia-induced dysfunction of ovarian response to endogenous gonadotropins. Rescuing the ovarian response to endogenous gonadotropins reduces hyperandrogenemia and re-establishes menstrual cyclicity and ovulation, increasing the chance of a spontaneous pregnancy. Among the insulin-sensitizing compounds, there is myo-inosiol (MYO). Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS. With the present review, we aim to provide an overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS.Keywords
This publication has 40 references indexed in Scilit:
- Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndromeHuman Reproduction, 2007
- Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemiaGynecological Endocrinology, 2007
- Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin?Journal of Clinical Endocrinology & Metabolism, 2006
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)Human Reproduction, 2004
- Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndromeFertility and Sterility, 2004
- Metformin in polycystic ovary syndrome: systematic review and meta-analysisBMJ, 2003
- Insulin-Lowering Agents in the Management of Polycystic Ovary SyndromeEndocrine Reviews, 2003
- Insulin Sensitizers for Polycystic Ovary SyndromeClinical Obstetrics and Gynecology, 2003
- Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndromeMetabolism, 1999
- Polycystic ovary syndrome--from gynaecological curiosity to multisystem endocrinopathyHuman Reproduction, 1996